Corteva (CTVA)
Develops seed genetics and crop-protection products for farmers worldwide.
$81.33
vs last close+0.98 (+1.23%)
In millions of USD, except per-share figures
| In millions | Q3 FY23Sep 2023 | Q4 FY23Dec 2023 | Q1 FY24Mar 2024 | Q2 FY24Jun 2024 | Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2,590 | 3,707 | 4,492 | 6,112 | 2,326 | 3,978 | 4,417 | 6,456 | 2,618 | 3,910 | 4,905 | 6,379 |
| Cost of revenue | 1,646 | 2,366 | 2,550 | 2,918 | 1,565 | 2,496 | 2,342 | 2,932 | 1,644 | 2,254 | 2,372 | 2,912 |
| Gross profit | 944 | 1,341 | 1,942 | 3,194 | 761 | 1,482 | 2,075 | 3,524 | 974 | 1,656 | 2,533 | 3,467 |
| 1,209 | 1,176 | 1,245 | 1,585 | 1,226 | 1,155 | 1,248 | 1,692 | 1,244 | 1,414 | 1,378 | 1,552 | |
| Research & development | 335 | 357 | 332 | 357 | 348 | 365 | 335 | 375 | 351 | 413 | 341 | 388 |
| 700 | 644 | 736 | 1,054 | 708 | 626 | 751 | 1,156 | 731 | 842 | 877 | 1,164 | |
| General & administrative | 700 | 0 | 736 | 1,054 | 708 | 0 | 751 | 1,156 | 731 | 0 | 877 | 0 |
| Other expenses | 174 | 175 | 177 | 174 | 170 | 164 | 162 | 161 | 162 | 159 | 160 | 0 |
| Operating income | −265 | 165 | 697 | 1,609 | −465 | 327 | 827 | 1,832 | −270 | 242 | 1,155 | 1,915 |
| −179 | −488 | −215 | −271 | −168 | −239 | −43 | −28 | −100 | −772 | −297 | −290 | |
| Interest income | 59 | 130 | 35 | 25 | 33 | 39 | 32 | 31 | 29 | 44 | 34 | 27 |
| Interest expense | 58 | 62 | 41 | 66 | 66 | 60 | 36 | 52 | 46 | 46 | 36 | 47 |
| Other non-operating income | 121 | 426 | 174 | 205 | 102 | 179 | 7 | −24 | 54 | 726 | 261 | 0 |
| Income before tax | −444 | −323 | 482 | 1,338 | −633 | 88 | 784 | 1,804 | −370 | −530 | 858 | 1,625 |
| Income tax expense | −129 | −92 | 106 | 282 | −114 | 138 | 117 | 422 | −62 | 7 | 133 | 408 |
| Net income from continuing operations | −315 | −231 | 376 | 1,056 | −519 | −50 | 667 | 1,382 | −308 | −537 | 725 | 1,217 |
| Discontinued operations | −3 | −20 | 47 | 0 | −2 | 11 | −11 | −66 | −10 | −12 | −2 | −52 |
| Net income | −321 | −253 | 419 | 1,053 | −524 | −41 | 652 | 1,314 | −320 | −552 | 720 | 1,161 |
| EPS, basic | −$0.45 | −$0.36 | $0.60 | $1.51 | −$0.76 | −$0.06 | $0.95 | $1.93 | −$0.47 | −$0.82 | $1.07 | $1.73 |
| EPS, diluted | −$0.45 | −$0.36 | $0.60 | $1.51 | −$0.76 | −$0.06 | $0.95 | $1.92 | −$0.47 | −$0.82 | $1.07 | $1.73 |
| Weighted average shares, basic | 708 | 704 | 700 | 696 | 691 | 687 | 685 | 682 | 679 | 675 | 673 | 670 |
| Weighted average shares, diluted | 708 | 704 | 703 | 698 | 691 | 687 | 687 | 683 | 679 | 675 | 674 | 672 |
| EBITDA | −80 | 51 | 830 | 1,716 | −261 | 450 | 1,116 | 2,157 | −24 | −178 | 1,191 | 2,254 |
| Depreciation & amortization | 306 | 312 | 307 | 312 | 306 | 302 | 296 | 301 | 300 | 306 | 297 | 339 |
| EBIT | −386 | −261 | 523 | 1,404 | −567 | 148 | 820 | 1,856 | −324 | −484 | 894 | 1,915 |
